Ending Gender Inequality in Cardiovascular Clinical Trial Leadership: JACC Review Topic of the Week
HGC Van Spall, A Lala, TF Deering, B Casadei… - Journal of the American …, 2021 - jacc.org
Women are under-represented as leaders of cardiovascular randomized controlled trials,
representing 1 in 10 lead authors of cardiovascular trials published in high-impact journals …
representing 1 in 10 lead authors of cardiovascular trials published in high-impact journals …
[HTML][HTML] Ending Gender Inequality in Cardiovascular Clinical Trial Leadership: JACC Review Topic of the Week
HGC Van Spall, A Lala, TF Deering, B Casadei… - Journal of the American …, 2021 - Elsevier
Women are under-represented as leaders of cardiovascular randomized controlled trials,
representing 1 in 10 lead authors of cardiovascular trials published in high-impact journals …
representing 1 in 10 lead authors of cardiovascular trials published in high-impact journals …
Ending Gender Inequality in Cardiovascular Clinical Trial Leadership: JACC Review Topic of the Week.
HGC Van Spall, A Lala, TF Deering… - Journal of the …, 2021 - europepmc.org
Women are under-represented as leaders of cardiovascular randomized controlled trials,
representing 1 in 10 lead authors of cardiovascular trials published in high-impact journals …
representing 1 in 10 lead authors of cardiovascular trials published in high-impact journals …
Ending Gender Inequality in Cardiovascular Clinical Trial Leadership: JACC Review Topic of the Week
HGC Van Spall, A Lala, TF Deering… - Journal of the …, 2021 - pubmed.ncbi.nlm.nih.gov
Women are under-represented as leaders of cardiovascular randomized controlled trials,
representing 1 in 10 lead authors of cardiovascular trials published in high-impact journals …
representing 1 in 10 lead authors of cardiovascular trials published in high-impact journals …
Ending Gender Inequality in Cardiovascular Clinical Trial Leadership
HGC van Spall, A Lala, TF Deering… - Journal of the …, 2021 - hal.univ-lorraine.fr
Women are under-represented as leaders of cardiovascular randomized controlled trials,
representing 1 in 10 lead authors of cardiovascular trials published in high-impact journals …
representing 1 in 10 lead authors of cardiovascular trials published in high-impact journals …